Patents for C07D 473 - Heterocyclic compounds containing purine ring systems (11,932) |
---|
06/05/2003 | US20030104974 Dual inhibitorsof PDE 7 and PDE 4 |
06/05/2003 | US20030104081 Composition for treating obesity and esthetic treatment process |
06/04/2003 | EP1315728A1 Process for the preparation of vitronectin receptor antagonists |
06/04/2003 | CN1110496C Tetrahydro Gamma-carbolines compound |
06/03/2003 | US6573378 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine having a purity of greater than 95% by weight or it's sodium salt |
06/03/2003 | US6573044 Methods of using chemical libraries to search for new kinase inhibitors |
05/29/2003 | US20030100574 Tricyclic 3,4-propinoperhydropurines; uses thereof for blocking neuronal transmission |
05/29/2003 | US20030100571 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease |
05/29/2003 | US20030100546 Neuropeptide Y antagonists |
05/29/2003 | US20030099686 Theobromine with an anti-carcinogenic activity |
05/28/2003 | EP1313737A1 Novel guanidino derivatives as inhibitors of cell adhesion |
05/28/2003 | EP1231211B1 Thiazolidinedione derivatives as antidiabetic agents |
05/28/2003 | CN1420887A 8-quinolinxanthine and 8-isoquinolinxanthine derivs. as PDE 5 inhibitors |
05/28/2003 | CN1109675C Arylpyrimidine derivs. |
05/27/2003 | US6569869 Annulated azole derivatives useful as microbicidal agents |
05/22/2003 | WO2003042214A2 A2b adenosine receptor antagonists |
05/22/2003 | WO2003042185A1 Xanthine oxidase inhibitors |
05/22/2003 | WO2003041647A2 Synthesis and purification of valacyclovir |
05/22/2003 | WO2003041642A2 Polymeric thiol-linked prodrugs employing benzyl elimination systems |
05/22/2003 | US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite |
05/22/2003 | US20030096836 2-Aroylimidazole compounds for treating cancer |
05/22/2003 | US20030096788 Adenosine derivatives |
05/22/2003 | US20030095992 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots |
05/22/2003 | CA2649826A1 Synthesis and purification of valacyclovir |
05/21/2003 | EP1311268A1 Imidazopyridine and imidazopyrimidine antiviral agents |
05/21/2003 | EP0784974B1 preparation of xanthine derivatives in a solid dispersion |
05/21/2003 | CN1419450A Nitrite salts of antimicrobial agents |
05/21/2003 | CN1109030C Processes for preparing intermediate product used in method of diastereoselective syntheses of nucleosides |
05/21/2003 | CN1108796C Use of anticancer material and production method of said anti-cancer material |
05/20/2003 | US6566509 Compound for use as bactericide |
05/20/2003 | US6566381 For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease |
05/20/2003 | CA2144962C 1-(2-oxo-acetyl)-piperidine-2-carboxylic acid derivatives as multi-drug-resistant cancer cell sensitizers |
05/15/2003 | WO2003040145A1 Anhydrous crystal form of valaciclovir hydrochloride |
05/15/2003 | WO2003040144A2 Heterocyclic compound based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds |
05/15/2003 | WO2003040096A2 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
05/15/2003 | US20030092909 Cyclin-dependent kinase inhibitor; antitumor, anticancer agents |
05/15/2003 | US20030092908 Autoimmune diseases; rheumatic diseases; multiple sclerosis; inflammatory bowel disease; immunosuppressants |
05/15/2003 | US20030092721 Antiinflammatory agents; rheumatic diseases |
05/15/2003 | CA2466284A1 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
05/15/2003 | CA2465420A1 Anhydrous crystal form of valaciclovir hydrochloride |
05/14/2003 | EP1310507A2 Novel peptide nucleic acids |
05/14/2003 | EP1192170B1 Propargyl phenyl ether a2a receptor agonists |
05/14/2003 | CN1418111A Novel Ligands and method for preparing same |
05/13/2003 | US6562969 Ricin inhibitors and methods for use thereof |
05/13/2003 | US6562819 Compounds for inhibition of ceramide-mediated signal transduction |
05/13/2003 | CA2021467C Heterocyclically substituted sulfonylureas, process for their preparation, and their use as herbicides or plant growth regulators |
05/08/2003 | WO2003037860A2 Purine analogs having hsp90-inhibiting activity |
05/08/2003 | WO2002094740A8 Hydrogenation processes performed in ionic liquids |
05/08/2003 | US20030087918 Substituted with purine or pyrimidine bases |
05/08/2003 | US20030087906 Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
05/08/2003 | US20030087904 Xanthine derivatives, such as 3-isobutyl-8-pyrrolidinylxanthine; treating asthma, diarrhea, etc. |
05/08/2003 | US20030087873 Treating a Flaviviridae, Orthomyxoviridae or Paramyxoviridae infection |
05/08/2003 | CA2464031A1 Purine analogs having hsp90-inhibiting activity |
05/07/2003 | EP1308447A1 Purine derivatives having antiproliferative properties and biological uses thereof |
05/07/2003 | EP0912520B1 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
05/06/2003 | US6559313 Adenosine derivatives such as (1S,2R,3S,4R)-2,3-dihydroxy-4-(6-(1-(4-trifluormethylpyridin-2-yl)pyrrolidin-3(S)-yl-amino)purin-9-yl)cyclopentanecarboxylic acid isopropylamide |
05/06/2003 | US6559293 Topiramate sodium trihydrate |
05/02/2003 | EP1306378A1 Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient |
05/02/2003 | EP1305290A1 Novel heteroaryl derivatives and the use thereof as pharmaceuticals |
05/02/2003 | EP1305028A2 Antimicrobial biaryl compounds |
05/02/2003 | EP1305026A2 Barbituric acid analogs as therapeutic agents |
05/02/2003 | EP1305023A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
05/01/2003 | WO2003035075A1 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
05/01/2003 | WO2003035009A2 Treatment of acute myeloid leukemia with indolinone compounds |
05/01/2003 | WO2002072581A3 Pyrazolopyriadine derivatives |
05/01/2003 | US20030083518 Substituted alcohols useful in treatment of Alzheimer's disease |
05/01/2003 | US20030083327 Inhibitors of Aurora-2 protein kinases and Glycogen synthase kinase-3 (GSK-3); cancer, diabetes, Alzheimer's disease, and schizophrenia treatment |
05/01/2003 | US20030079311 Suspension bushing, motor vehicle and a suspension cross-member for a motor vehicle |
05/01/2003 | CA2464790A1 Treatment of acute myeloid leukemia with indolinone compounds |
04/29/2003 | US6555687 Chloropyrimidine intermediates |
04/29/2003 | US6555685 Preparing purine derivatives, such as famiciclovir and penciclovir, by reacting, in the presence of a palladium catalyst and ligand; by-product inhibition; efficiency |
04/29/2003 | US6555572 Benzylated PDE4 inhibitors |
04/29/2003 | US6555545 Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents |
04/24/2003 | WO2003033498A2 A process for the treatment of ganciclovir intermediate n2-acetyl-9-(1, 3-diacetoxy-2-propoxymethyl) guanine |
04/24/2003 | WO2003032989A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
04/24/2003 | WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors |
04/24/2003 | WO2002045707A3 Polynucleotide intercalator interceptors and inhibitors |
04/24/2003 | US20030078275 For therapy of cancer, diabetes and Alzheimer's disease |
04/24/2003 | US20030078166 Pyrazole compounds useful as protein kinase inhibitors |
04/24/2003 | CA2462441A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
04/23/2003 | EP1304046A1 Theobromine with an anti-carcinogenic activity |
04/23/2003 | EP1303641A2 Method for recovery of copper from sulfidic ore materials using super-fine grinding and medium temperature pressure leaching |
04/23/2003 | EP1220863B1 Purine derivatives |
04/23/2003 | CN1413216A Azolyalkyl-oxa (di) azolyl pyri (mi) dine derivatives, method for their production and use as pesticides |
04/23/2003 | CN1411813A Theobromine with anticancer activity |
04/22/2003 | US6552193 Chloropyrimidine intermediates |
04/22/2003 | US6552192 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof |
04/22/2003 | US6552073 Compounds and methods of treating cell proliferative diseases |
04/22/2003 | CA2239187C Inhibitors of farnesyl protein transferase |
04/17/2003 | WO2003031406A2 Kinase inhibitor scaffolds and methods for their preparation |
04/17/2003 | WO2003031405A2 Methods for the synthesis of substituted purines |
04/17/2003 | US20030073834 Purine compounds having PDE IV inhibitory activity and methods of synthesis |
04/17/2003 | US20030073687 Alzheimer's disease; anticancer agents; antidiabetic agents |
04/17/2003 | US20030072965 Electroluminescence device for use in display devices, backlights, electro-photographies, illumination light sources, recording light sources, exposing light sources, reading light sources, road signs and markings, optical communication |
04/17/2003 | CA2463563A1 Kinase inhibitor scaffolds and methods for their preparation |
04/17/2003 | CA2463507A1 Methods for the synthesis of substituted purines |
04/16/2003 | EP1301829A1 Radiation sensitive compositions containing image quality and profile enhancement additives |
04/16/2003 | EP1301187A2 Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
04/16/2003 | EP1150981B1 Use of (1r, 4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol in hbv |
04/16/2003 | EP0674634B1 Process for preparing substituted 1,3-oxathiolanes with antiviral properties |